A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy with an Open-Label Extension
|Male and Female Patients
|U.S. Govt. ID:
|Evelyn Dominguez-Rivera: 212 -305 -2371 / firstname.lastname@example.org
The Primary objective of the study is to evaluate the efficacy of the study drug, compared to placebo, as measured by a change from baseline in the PSP Rating Scale (PSPRS) after one year, and to assess the safety and tolerability of the study drug, relative to placebo.
This study is closed
Lawrence Honig, MD, PhD
|Do you have Progressive Supranuclear Palsy?
|Do you have a primary caregiver?